Reduction of myocardial infarct size remains an important objective in reperfusion therapy. Timely mechanical or pharmacological reperfusion is essential, but beyond that, acute therapies to reduce infarct size and limit reperfusion injury are largely lacking. Erythropoietin had been demonstrated to reduce infarct size in experimental models, although the data are somewhat mixed.1- 8 Therefore, it would seem to be a logical agent to test prospectively in a trial of acute myocardial infarction (MI).9
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 7
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Original Article: Does This Patient Have a Hemorrhagic Stroke?
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.